PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Flavia Castelino, MD / Sonye K. Danoff, MD, PhD - The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management


Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.


share







 2020-12-29  1h21m